QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Biosimilars and Generic Medicines—Regulatory and Pharmacovigilance Differences

Test your understanding of the concepts covered by Biosimilars and Generic Medicines: Regulatory and Pharmacovigilance Differences.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best characterises the role of the reference medicine in biosimilar assessment?

It is used only to provide the invented name of the proposed product It provides prior biological and clinical knowledge and serves as the comparator in a structured similarity assessment It becomes the legally recorded exposure whenever a biosimilar adverse reaction is reported It is relevant only after authorisation and has no role in development

Question 2 of 10 Which operational control best supports reliable biosimilar pharmacovigilance?

Recording only the active substance and omitting the product name and batch Maintaining product-level identification, batch information where relevant and reconstructable switching and exposure history Replacing all biosimilar cases with the corresponding reference-product code Preventing any use of aggregated analyses

Question 3 of 10 Which product-specific issue could be relevant to pharmacovigilance for either a generic or a biosimilar?

Only a change in the reference medicine's indication Formulation, excipient, manufacturing, contamination, dose-delivery or other quality-related problems Only the molecular size of the active substance Only a failure to demonstrate bioequivalence

Question 4 of 10 A pharmacovigilance assessor states that a biosimilar is 'the same product' as its reference because the products are scientifically interchangeable. What is the best correction?

Interchangeability eliminates the need to identify the administered product Scientific interchangeability means that the biosimilar is no longer a distinct medicinal product A biosimilar may be scientifically interchangeable while remaining a distinct authorised product that must be identifiable in safety surveillance Interchangeability applies only to generic medicines and cannot apply to biosimilars

Question 5 of 10 What is the central scientific objective of a conventional generic development programme?

To demonstrate high similarity across analytical, functional and clinical attributes of a biological product To establish pharmaceutical quality and the applicable form of equivalence, including bioequivalence where required To identify all possible immunogenic responses before authorisation To repeat the reference medicine's full efficacy and safety development programme

Question 6 of 10 Which pharmacokinetic distinction is most accurate?

Pharmacokinetics is relevant to generics but not to biosimilars Generic bioequivalence commonly focuses on comparable exposure measures, while biological-product PK may require broader consideration of distribution and elimination Biosimilar PK assessment is limited to absorption because biological products do not undergo elimination Comparable pharmacokinetics automatically proves identical immunogenicity

Question 7 of 10 Which statement best describes the relationship between pharmacovigilance and quality systems?

Pharmacovigilance should independently determine manufacturing causality without quality input Quality systems should resolve all clinical safety questions without pharmacovigilance assessment Safety reports and quality complaints should have controlled interfaces because either may contain information relevant to the other function Quality information is relevant only for biosimilars and never for generics

Question 8 of 10 What is the most appropriate distinction between EU scientific interchangeability and automatic substitution?

They are identical concepts controlled exclusively by EMA Scientific interchangeability is a conclusion about use of authorised biosimilars, whereas automatic substitution is a national policy decision Automatic substitution establishes biosimilarity, while scientific interchangeability concerns only pricing Neither concept has any relevance to exposure reconstruction

Question 9 of 10 Which conclusion about safety should a professional avoid when comparing generics and biosimilars?

The two categories use different scientific and regulatory evidence strategies Biological-product characteristics make traceability and immunogenicity particularly important considerations for biosimilars One category is inherently safer than the other solely because its regulatory pathway is different Reference-product knowledge can inform safety assessment in both categories

Question 10 of 10 Which statement best explains why generic development usually does not repeat the reference medicine's full efficacy trials?

Generic medicines are exempt from efficacy considerations The active substance and reference clinical knowledge are established, so the generic programme focuses on meeting the applicable quality and equivalence conditions Generic applicants are allowed to rely only on spontaneous adverse-event reports Efficacy trials are unnecessary for every medicinal product

Knowledge Assessment: Biosimilars and Generic Medicines—Regulatory and Pharmacovigilance Differences

Cookie Settings